|
US2007021412A1
|
|
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
|
|
US2006128955A1
|
|
Method of isolating (R)-tofisopam
|
|
CA2562078A1
|
|
Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
|
|
AU2005201012A1
|
|
Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof
|
|
US2005227961A1
|
|
Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
|
|
WO2004103154A2
|
|
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
|
|
US2004229866A1
|
|
Method of lowering body temperature with (S)-2,3-benzodiazepines
|
|
CA2510275A1
|
|
Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
|
|
US6683072B1
|
|
Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
|
|
US7022700B2
|
|
Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
|
|
US6864251B2
|
|
Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
|
|
US6638928B1
|
|
Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
|
|
AU2002312478A1
|
|
(r, r'),(r',s')-amphetaminil, compositions and uses thereof
|
|
AU2002320078A1
|
|
(s, s'), (s, r')-amphetaminil, compositions and uses thereof
|
|
ZA200203408B
|
|
Compositions and methods for treating or preventing convulsions or seizures.
|
|
US6649607B2
|
|
Compositions and methods for treating or preventing convulsions or seizures
|
|
WO0134172A2
|
|
Methods and compositions for treating reward deficiency syndrome
|
|
ES2212737A1
|
|
CYCLLOBENZAPRINE TO TREAT DISORDERS OF GENERAL ANXIETY AND COMPOSITIONS OF THE SAME.
|
|
NZ516749A
|
|
Uses compositions for treating or preventing sleep disturbances using doses of cyclobenzaprine of less than 5mg/day
|
|
MXPA01001178A
|
|
Methods and compositions for treating and preventing certain psychiatric and medical disorders using moclobemide.
|
